Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL.

被引：0
|
作者：
Wierda, WG [1 ]
OBrien, S [1 ]
Ferrajoli, A [1 ]
Faderl, S [1 ]
Koller, C [1 ]
Giles, F [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Ravandi, F [1 ]
Garcia-Manero, G [1 ]
Andreeff, M [1 ]
Lerner, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
719
引用
收藏
页码：213A / 213A
页数：1
相关论文
共 48 条
  • [1] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL.
    Wierda, William G.
    O'Brien, Susan
    Faderl, Stefan
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Cortes, Jorge
    Giles, Francis
    Andreeff, Michael
    Koller, Charles Asa
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2006, 108 (11) : 14A - 14A
  • [2] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL
    Wierda, W
    Faderl, S
    O'Brien, S
    Cortes, J
    Ferrajoli, A
    Giles, F
    Andreff, M
    Koller, C
    Kantarjian, H
    Keating, M
    BLOOD, 2004, 104 (11) : 101A - 101A
  • [3] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
    Wierda, W
    O'Brien, S
    Ferrajoli, A
    Faderl, S
    Kornblau, SM
    Andreef, M
    Koller, C
    Garcia-Manero, G
    Thomas, D
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 360B - 360B
  • [4] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wang, Xuemei
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Lerner, Susan
    Kantarjian, Hagop
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2085 - 2093
  • [5] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL
    Wierda, William G.
    O'Brien, S.
    Ferrajoli, A.
    Faderl, S.
    Koller, C.
    Estrov, Z.
    Garcia-Manero, G.
    Verstovsek, S.
    Browning, M.
    Lerner, S.
    Keating, M.
    BLOOD, 2007, 110 (11) : 194A - 194A
  • [6] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Ricci, Francesca
    Vismara, Eleonora
    Ciapanna, Denis
    Petrizzi, Valeria Belsito
    Crugnola, Monica
    Spriano, Mauro
    Uziel, Lilj
    De Blasio, Angelo
    Spedini, Pierangelo
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 922A - 922A
  • [7] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Rupert Bartsch
    Catharina Wenzel
    Simon P. Gampenrieder
    Ursula Pluschnig
    Gabriela Altorjai
    Margaretha Rudas
    Robert M. Mader
    Peter Dubsky
    Andrea Rottenfusser
    Michael Gnant
    Christoph C. Zielinski
    Guenther G. Steger
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 903 - 910
  • [8] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Bartsch, Rupert
    Wenzel, Catharina
    Gampenrieder, Simon P.
    Pluschnig, Ursula
    Altorjai, Gabriela
    Rudas, Margaretha
    Mader, Robert M.
    Dubsky, Peter
    Rottenfusser, Andrea
    Gnant, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 903 - 910
  • [9] Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
    Tam, Constantine S.
    O'Brien, Susan
    Plunkett, William
    Wierda, William
    Ferrajoli, Alessandra
    Wang, Xuemei
    Do, Kim-Anh
    Cortes, Jorge
    Khouri, Issa
    Kantarjian, Hagop
    Lerner, Susan
    Keating, Michael J.
    BLOOD, 2014, 124 (20) : 3059 - 3064
  • [10] Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL)
    Eichhorst, Barbara F.
    Fischer, Kirsten
    Fink, Anna-Maria
    Fingerle-Rowson, Guenter
    Westermann, Anne
    Wendtner, Clemens-Martin
    Busch, Raymonde
    Hallek, Michael
    BLOOD, 2009, 114 (22) : 1336 - 1336
12345